Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

Publisher： Karger

E-ISSN： 1423-0232|79|1-2|85-92

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.1-2, 2010-11, pp. : 85-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 350-354

Karger

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 84, Iss. 2, 2012-11 ,pp. : 108-114

Karger

Access to resources Recommend Favorite

The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 85, Iss. 5, 2013-11 ,pp. : 312-316

Karger

Access to resources Recommend Favorite

Letter: sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV‐infected patients

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1414-1416

John Wiley & Sons Inc

Access to resources Recommend Favorite